Get personalized medicine

Precision Medicine means tailoring medical treatments to the individual characteristics of each patient.

Today, physicians are able to target the unique nature of an individual patient’s tumor by matching treatments at the molecular level, resulting in improved outcome.

Already in 2011, a study from MD Anderson Cancer Center found that patients with advanced cancers treated with the traditional or standard of care, which is based on their type or origin of cancer rather than their DNA tumor profile, had a mere 5% response rate to their treatment.

The same study found that when patients with metastatic cancers were treated using a personalized approach, matching them at the molecular level, there was a 27% response rate.This was the beginning of personalized medicine using DNA. OmiCure™ goes one step further using RNA and it is available now.
DISCOVER OMICURE™

What results can I expect?

Based on your personal results, your oncologist may propose a targeted therapy.

Alternatively, with the help of OmiCure™, the physician may avoid using a drug, which he or she would have other otherwise propose, due to expected inefficiency. Therefore saving you time in your fight against cancer, and preventing unnecessary adverse events from an ineffective therapy.

Using all information at hand, the oncologist may propose to continue the same therapy in the same oncology center, using traditional treatments or experimental drugs in clinical trial stage. Or, it may happen that you will be advised to participate in a clinical trial conducted in another oncology center (near you, within your country or abroad), in which an active substance is currently being evaluated, and which was specifically developed against tumors with the same characteristics as yours.

It can also happen that no DNA alterations or gene expression changes are detected. This does not mean that the information obtained is useless. As a matter of fact, the absence of certain gene mutations may increase the efficacy of targeted treatments that influence other genes.
OmiCure  cancer Tumor Profiling genomic DNA & RNA AI test  - artificial Inteligence

OmiCure™ cannot assess whether a drug is appropriate or gauge a patient’s ability to respond to any specific medication. Patients should not look to the report for medical advice or to make treatment decisions on their own; instead, they should only use the information to guide discussions with their health care provider.
OmiCure  cancer Tumor Profiling genomic DNA & RNA AI test  - artificial InteligenceOmiCure  cancer Tumor Profiling genomic DNA & RNA AI test  - artificial InteligenceOmiCure  cancer Tumor Profiling genomic DNA & RNA AI test  - artificial Inteligence

Your oncologist needs Omicure™

It would take years for your oncologist to sort through an entire library of the latest FDA-approved drugs and published research, and decide which one could provide the best outcomes based on your genomic making.

OmiCure™ provides a clear report of ranked drug therapies based on information collected at the genomic level. This report is designed to provide concise, actionable knowledge and insights for your oncologist. Ultimately, the report enables the patient and caregiving team to make the best treatment decisions possible.

Why is the current standard of care not working?

Doctors and patients have traditionally relied upon “one-size-fits-all” treatments and procedures.

They include chemotherapy, radiation therapy and surgery, aimed largely at fighting a particular type or origin of cancer (e.g. breast, prostate, pancreatic, etc.) rather than target the unique nature of an individual patient’s cancer. This is despite one’s genotype and phenotype having a profound influence on clinical responses to targeted anticancer therapies.

In fact, patients with the same cancer diagnosis not only are unlikely to share the same specific genetic background but are also unlikely to have the same exact reactions to identical treatments. Thus, cancer must be viewed as a personal disease, with personalized precision treatments to best counteract each specific disease.
OmiCure  cancer Tumor Profiling genomic DNA & RNA AI test  - artificial InteligenceOmiCure  cancer Tumor Profiling genomic DNA & RNA AI test  - artificial Inteligence
OmiCure  cancer Tumor Profiling genomic DNA & RNA AI test  - artificial Inteligence

Does the report show hereditary cancer risks?

The OmiCure™ report is not a hereditary genetic testing service, since the gene mutations and the gene expression differences we detect are not typically congenital or inherited gene defects.

Therefore, OmiCure™’s report results do not show your or your relatives’ potential cancer risk. If you are interested in whether you or your relatives have a higher risk of cancer we can recommend you to genetic counseling services.

Genomic testing and genetic testing give us more information

Genetic testing detects hereditary (mainly inherited from parents) alterations in DNA while genomic testing primarily detects acquired somatic (over the course of a lifetime) alterations in DNA. Sometimes, genomics testing can also be used as an umbrella term to include transcriptomics, which measures how much each gene is transcribed into mRNA (RNA expression).

Acquired alterations and differences in gene expression are thought to be responsible for the majority of cancers and may impact tumor growth, spread, and response to therapy.
OmiCure  cancer Tumor Profiling genomic DNA & RNA AI test  - artificial Inteligence